Meropenem Fresenius Kabi

Meropenem, the active ingredient in Meropenem Fresenius Kabi, is a carbapenem antibiotic presented as an injectable solution for intravenous use. It treats severe bacterial infections such as complicated intra‑abdominal infections, complicated urinary tract infections, complicated skin and soft tissue infections, nosocomial pneumonia, severe sepsis, septic shock, and meningitis in hospitalized patients.

GNH USA supplies Meropenem Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Meropenem is a broad‑spectrum carbapenem used for serious infections that require intravenous therapy.

- Complicated intra‑abdominal infection: provides bacterial eradication and clinical cure in hospitalized patients. - Complicated urinary tract infection: eliminates resistant Gram‑negative pathogens causing severe UTIs. - Complicated skin and soft tissue infection: achieves rapid resolution of deep tissue infections. - Nosocomial pneumonia: treats hospital‑acquired lung infections caused by multidrug‑resistant organisms. - Severe sepsis and septic shock: offers life‑saving coverage against broad bacterial spectra. - Meningitis: penetrates the cerebrospinal fluid to eradicate causative bacteria.

Adverse reactions may occur with any intravenous antibiotic. Monitoring for side effects is recommended during therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal discomfort. - Diarrhea: may be watery and self‑limited. - Headache: transient and usually resolves after treatment. - Rash: erythematous skin eruption. - Elevated liver enzymes: transient increase in transaminases. - Injection site pain: local discomfort during infusion.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or CNS disorders. - Clostridioides difficile‑associated diarrhea: severe colitis risk. - Anaphylaxis: acute hypersensitivity reaction. - Severe neutropenia: marked reduction in white blood cells. - Renal toxicity: worsening kidney function. - Stevens‑Johnson syndrome: rare severe skin reaction.

Careful assessment and monitoring are required before and during treatment with Meropenem.

- Renal function assessment: adjust dose in patients with impaired renal function. - Allergy history: avoid in individuals with known hypersensitivity to carbapenems or β‑lactams. - Seizure risk: monitor patients with central nervous system disorders or those receiving high doses. - Pregnancy: use only if the potential benefit justifies the potential risk to the fetus. - Drug interactions: review concomitant medications for additive nephrotoxicity or seizure risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem may interact with several concomitant medicines; some require avoidance while others need close monitoring.

Major Interactions (Avoid): - Valproic acid: may increase risk of seizures. - Cisplatin: additive nephrotoxicity. - Loop diuretics: may exacerbate renal impairment. - Probenecid: can reduce renal clearance of Meropenem. - Other nephrotoxic antibiotics: heightened risk of kidney injury.

Moderate Interactions (Monitor Closely): - Aminoglycosides: monitor renal function and serum drug levels. - Vancomycin: watch for combined nephrotoxic effects. - Warfarin: may affect INR, require coagulation monitoring. - Oral contraceptives: possible reduction in efficacy, advise backup method. - Phenytoin: may alter serum concentrations, adjust dosing as needed.